These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9089712)

  • 1. A color spot test for the detection of Kryptofix 2.2.2 in [18F]FDG preparations.
    Mock BH; Winkle W; Vavrek MT
    Nucl Med Biol; 1997 Feb; 24(2):193-5. PubMed ID: 9089712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thin layer chromatographic detection of kryptofix 2.2.2 in the routine synthesis of [18F]2-fluoro-2-deoxy-D-glucose.
    Chaly T; Dahl JR
    Int J Rad Appl Instrum B; 1989; 16(4):385-7. PubMed ID: 2777579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elimination of contaminant Kryptofix 2.2.2 in the routine production of 2-[18F]fluoro-2-deoxy-D-glucose.
    Moerlein SM; Brodack JW; Siegel BA; Welch MJ
    Int J Rad Appl Instrum A; 1989; 40(9):741-3. PubMed ID: 2559062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct analysis of Kryptofix 2.2.2 in 18FDG by gas chromatography using a nitrogen-selective detector.
    Ferrieri RA; Schlyer DJ; Alexoff DL; Fowler JS; Wolf AP
    Nucl Med Biol; 1993 Apr; 20(3):367-9. PubMed ID: 8485498
    [No Abstract]   [Full Text] [Related]  

  • 5. Determination of residual Kryptofix 2.2.2 levels in [18F]-labeled radiopharmaceuticals for human use.
    Scott PJ; Kilbourn MR
    Appl Radiat Isot; 2007 Dec; 65(12):1359-62. PubMed ID: 17582776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous analysis of FDG, ClDG and Kryptofix 2.2.2 in [18F]FDG preparation by high-performance liquid chromatography with UV detection.
    Nakao R; Ito T; Yamaguchi M; Suzuki K
    Nucl Med Biol; 2008 Feb; 35(2):239-44. PubMed ID: 18312835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Back-to-back "one-pot" [18F]FDG syntheses in a single Siemens-CTI chemistry process control unit.
    Mock BH; Vavrek MT; Mulholland GK
    Nucl Med Biol; 1996 May; 23(4):497-501. PubMed ID: 8832706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of Kryptofix 2.2.2 in 2-[(18)F]FDG and other radiopharmaceuticals by LC/MS/MS.
    Ma Y; Huang BX; Channing MA; Eckelman WC
    Nucl Med Biol; 2002 Jan; 29(1):125-9. PubMed ID: 11786283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of Kryptofix 2.2.2 in [18F]fluorine-labelled radiopharmaceuticals by rapid-resolution liquid chromatography.
    Lao Y; Yang C; Zou W; Gan M; Chen P; Su W
    Nucl Med Commun; 2012 May; 33(5):498-502. PubMed ID: 22330082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of 2-[18F]fluoro-2-deoxy-D-glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomography.
    Osman S; Danpure HJ
    Int J Rad Appl Instrum B; 1992 Feb; 19(2):183-90. PubMed ID: 1601671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the yield of 2-[18F]fluoro-2-deoxyglucose using a microwave cavity.
    Taylor MD; Roberts AD; Nickles RJ
    Nucl Med Biol; 1996 Jul; 23(5):605-9. PubMed ID: 9044687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Removal of the 2.2.2 cryptand (Kryptofix 2.2.2) from 18FDG by cation exchange.
    Alexoff DL; Fowler JS; Gatley SJ
    Int J Rad Appl Instrum A; 1991; 42(12):1189-93. PubMed ID: 1668801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fully automated [18F]fluorocholine synthesis in the TracerLab MX FDG Coincidence synthesizer.
    Kryza D; Tadino V; Filannino MA; Villeret G; Lemoucheux L
    Nucl Med Biol; 2008 Feb; 35(2):255-60. PubMed ID: 18312837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simple synthesis of F-18-labeled 2-fluoro-2-deoxy-D-glucose: concise communication.
    Ehrenkaufer RE; Potocki JF; Jewett DM
    J Nucl Med; 1984 Mar; 25(3):333-7. PubMed ID: 6699724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucose transporter protein-independent tumor cell accumulation of fluorine-18-AFDG, a lipophilic fluorine-18-FDG analog.
    Waki A; Fujibayashi Y; Magata Y; Yokoyama A; Sadato N; Tsuchida T; Ishii Y; Yonekura Y
    J Nucl Med; 1998 Feb; 39(2):245-50. PubMed ID: 9476929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New high-yield synthesis of 18F-labelled 2-deoxy-2-fluoro-D-glucose.
    Diksic M; Jolly D
    Int J Appl Radiat Isot; 1983 Jun; 34(6):893-6. PubMed ID: 6874115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modular automation in PET tracer manufacturing: application of an autosynthesizer to the production of 2-deoxy-2-[18F]fluoro-D-glucose.
    Alexoff DL; Russell JA; Shiue CY; Wolf AP; Fowler JS; MacGregor RR
    Int J Rad Appl Instrum A; 1986; 37(10):1045-61. PubMed ID: 3027001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simple rapid hydrolysis of acetyl protecting groups in the FDG synthesis using cation exchange resins.
    Mulholland GK
    Nucl Med Biol; 1995 Jan; 22(1):19-23. PubMed ID: 7735165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ion chromatographic analysis of high specific activity 18FDG preparations and detection of the chemical impurity 2-deoxy-2-chloro-D-glucose.
    Alexoff DL; Casati R; Fowler JS; Wolf AP; Shea C; Schlyer DJ; Shiue CY
    Int J Rad Appl Instrum A; 1992 Nov; 43(11):1313-22. PubMed ID: 1333458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Errors introduced by tissue heterogeneity in estimation of local cerebral glucose utilization with current kinetic models of the [18F]fluorodeoxyglucose method.
    Schmidt K; Lucignani G; Moresco RM; Rizzo G; Gilardi MC; Messa C; Colombo F; Fazio F; Sokoloff L
    J Cereb Blood Flow Metab; 1992 Sep; 12(5):823-34. PubMed ID: 1506447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.